Introduction {#s1}
============

Pancreatic β-cell ATP-sensitive potassium (K~ATP~) channels are a critical link between nutrient metabolism and insulin secretion, maintaining the blood sugars in a narrow physiological range. In fasted animals, K~ATP~ channels provide the dominant β-cell membrane conductance, maintaining the cell in a hyperpolarized state and stopping insulin secretion. Conversely, in the fed state, glucose metabolism increases the \[ATP\]/\[ADP\] ratio, closing K~ATP~ channels, causing membrane depolarization and voltage-dependent Ca^2+^ entry, which in turn trigger insulin secretion \[[@pmed-0050206-b001]\].

The K~ATP~ channel is a heteroctameric complex composed of four inwardly rectifying K^+^ channel subunits (Kir6.2) and four sulfonylurea (SU) receptors (SUR1) \[[@pmed-0050206-b002]\]. Loss-of-function mutations of β-cell K~ATP~ channel subunits (SUR1, *ABCC8*, OMIM accession number 600509; and Kir6.2, *KCNJ11*, OMIM 600937; GenBank, <http://www.ncbi.nlm.nih.gov/>) underlie congenital hyperinsulinism (HI) in humans \[[@pmed-0050206-b003]--[@pmed-0050206-b007]\], a genetic disease characterized by relative hyperinsulinemia and hypoglycemia \[[@pmed-0050206-b008]\]. In HI, reduced or absent K~ATP~ channel activity is expected to result in constitutive depolarization, elevated intracellular \[Ca^2+^\], and hypersecretion of insulin \[[@pmed-0050206-b009]\]. In order to replicate the human disease, mice lacking Kir6.2 or SUR1 and mice expressing dominant-negative mutant Kir6.2-encoding transgenes have been generated. Kir6.2- or SUR1-knockout (KO) mice show insulin hypersecretion immediately after birth, but rapidly and unexpectedly progress to glucose intolerance and insulin hyposecretion as adults \[[@pmed-0050206-b010]--[@pmed-0050206-b012]\]. Conversely, the β-cell--specific Kir6.2\[AAA\] dominant-negative mouse \[[@pmed-0050206-b013]\] demonstrates only a ∼70% decrease in β-cell K~ATP~ channel activity, and exhibits insulin hypersecretion with hyperinsulinemia that persist through adulthood. Heterozygous Kir6.2^+/−^ and SUR1^+/−^ mice, which also have reduced K~ATP~ gene dosage (∼60%), also show enhanced glucose tolerance and glucose-sensitive insulin secretion (GSIS) that is maintained throughout adulthood, without progression to secretory failure \[[@pmed-0050206-b014]\].

We therefore conclude that varying degrees of genetic suppression of K~ATP~ channel activity will all lead to enhanced excitability, but with different long-term consequences for insulin secretion, depending on the severity of suppression: incomplete loss of K~ATP~ channels (e.g., in Kir6.2\[AAA\] \[[@pmed-0050206-b013]\] or in heterozygous Kir6.2^+/−^ or SUR1^+/−^ mice \[[@pmed-0050206-b014]\]) causes a maintained hyperinsulinism, whereas complete loss (in Kir6.2- and SUR1-KO mice) causes transient hypersecretion that is followed by a secretory deficit and reduced glucose tolerance \[[@pmed-0050206-b010]--[@pmed-0050206-b012]\]. The recombinant phenotypes of many HI mutations \[[@pmed-0050206-b006],[@pmed-0050206-b015],[@pmed-0050206-b016]\] actually suggest that reduced, but not complete, absence of K~ATP~ channels \[[@pmed-0050206-b017]\] is likely. Henwood et al. \[[@pmed-0050206-b018]\] have demonstrated that some HI patients with K~ATP~ channel mutations clearly maintain some K~ATP~ channel activity, because the patients were responsive to K~ATP~ channel drugs. There are also limited reports that some HI patients, even those nonsurgically treated, can spontaneously progress to type 2 diabetes \[[@pmed-0050206-b019]--[@pmed-0050206-b021]\]. HI is also often present at the onset of clinically overt type 2 diabetes, which is interpreted as the endocrine pancreas trying to compensate for primary defects in insulin sensitivity in the peripheral tissues \[[@pmed-0050206-b022]\]. Thus the progression from relative to absolute insulin deficiency by decreasing insulin secretory capacity appears as the result of a detrimental long-term increased workload of β-cells \[[@pmed-0050206-b023]\].

SUs, such as tolbutamide and glibenclamide (glyburide), are widely used in patients with type 2 diabetes, because they induce insulin secretion independently of the metabolic state of the β-cell \[[@pmed-0050206-b024]--[@pmed-0050206-b026]\]. These antidiabetic drugs bind to the SUR1 subunit, leading to inhibition of K~ATP~ channel activity, membrane depolarization, and insulin secretion. Patients with type 2 diabetes chronically treated with SUs often progress to a failure of β-cells to secrete insulin \[[@pmed-0050206-b027]--[@pmed-0050206-b029]\]. The systemic or cellular mechanism underlying such failure is not well understood, although it could be linked either to the evolution of the disease or to a specific effect of the drugs \[[@pmed-0050206-b030]--[@pmed-0050206-b032]\]. Consistent with all these studies, the UK Prospective Diabetes Study (UKPDS) revealed that 48% of the patients with type 2 diabetes treated for 6 y with glibenclamide required additional therapy to maintain their normal blood sugars \[[@pmed-0050206-b033]\].

Despite the widespread use of SUs, there is also evidence that chronic SU (tolbutamide and glibenclamide) treatment may induce Ca^2+^-dependent β-cell apoptosis in rat islets \[[@pmed-0050206-b034]\] and human islets incubated with glibenclamide demonstrated a significant decrease in insulin content (24 h incubation), as well as an approximate 2-fold increase in β-cell apoptosis (4 d incubation) \[[@pmed-0050206-b035],[@pmed-0050206-b036]\]. Glibenclamide-treated Min6 cells reportedly also showed a reversible reduction in insulin content and an accelerated apoptotic β-cell death \[[@pmed-0050206-b037]--[@pmed-0050206-b039]\], although SU (glibenclamide)-induced apoptosis was apparently specifically enhanced only by expression of the receptor SUR1, but not SUR2B, in HEK 293 cells \[[@pmed-0050206-b040]\].

The parallels between the long-term consequence of genetic hyperexcitability in mice and desensitization/apoptosis to prolonged SU treatment in humans lead us to hypothesize that, in vivo, SUs will induce an increase in electrical activity leading to enhanced insulin secretion in the short term, but that in the longer term they may still cause membrane hyperexcitability but paradoxically lead to insulin secretory failure, reproducing the K~ATP~ channel KO mouse phenotype. In this paper we specifically tested this hypothesis using a novel pharmacological approach by implanting slow-release (90 d) SU (glibenclamide) pellets.

Methods {#s2}
=======

Animals {#s2a}
-------

Wild-type C57BL/6 mice were obtained from Jackson Laboratories (6-wk-old males, JAX mice; <http://jaxmice.jax.org/>). Kir6.2 KO mice (a gift from Dr. Susumo Seino) were originally generated by targeted disruption of the gene encoding Kir6.2 in the 129Sv mouse strain \[[@pmed-0050206-b010]\]. SUR1 KO mice (a gift from Dr. Mark Magnuson) were originally generated in the C57BL/6 mice by pronuclear microinjection of 1 ng/μl *CMV-Cre* expression vector (pBS185) into embryos obtained from a mating of *Sur1^lox+neo^* ^/*w*^ and *Sur1^w^* ^/*w*^ mice \[[@pmed-0050206-b011]\]. All experiments were performed in compliance with the relevant laws and institutional guidelines, and were approved by the Washington University Animal Studies Committee.

Acute Glibenclamide Injection in Wild-Type C57BL/6 Mice {#s2b}
-------------------------------------------------------

Fed wild-type (WT) mice were acutely injected with glibenclamide (0, 1, 3, 10, and 30 μg) and tested for blood glucose levels over time. Intraperitoneal glucose--glibenclamide tolerance tests were performed in fasted (12 h) 6-wk-old WT mice by simultaneous injection of a bolus of glucose (1.5 g/kg) plus glibenclamide at the indicated doses. Glibenclamide responsivity following implantation was assessed by injection of 30 μg/ml in fed mice. Blood was assayed for glucose content using the Glucometer Elite XL (Bayer, <http://www.bayer.com>).

Blood Glucose and Plasma Insulin Measurements on Mice Implanted with Glibenclamide Pellets {#s2c}
------------------------------------------------------------------------------------------

Glibenclamide (glyburide) pellets at the concentration of 0.0001, 0.001, 0.025, 0.25, and 2.5 mg per 90-d release were obtained from Innovative Research of America (Sarasota, FL). Six-week old males were anesthetized with tribromoethanol (Avertin; 0.25 mg/g mouse body weight). The skin on the lateral side of the neck of the animal was lifted and pellets were implanted under the skin of the neck using a stainless steel precision trochar. Blood samples taken from the tail vein in fed and fasting conditions, and during glucose tolerance tests (GTTs), were assayed for glucose content as described above. Intraperitoneal GTTs were performed in WT, Kir6.2-KO, and SUR1-KO mice implanted with different glibenclamide pellet concentrations. For insulin tolerance tests (ITTs), mice were injected with 0.5 U insulin/kg following 6-h fasting. Blood was taken at different times (as indicated in figures) and assayed for glucose content. Plasma insulin was measured on glibenclamide-treated mice at 2 d and 42 d after pellet implantation using a rat insulin ELISA kit.

Islet Isolation {#s2d}
---------------

Mice were anesthetized with halothane (0.2 ml) in an anesthetizing chamber and killed by cervical dislocation. Pancreata were removed and injected with Hank\'s balanced salt solution (HBSS; Sigma-Aldrich, <http://www.sigmaaldrich.com/>) containing collagenase (0.3 mg/ml) (pH 7.4). Collagenase type XI was obtained from Sigma-Aldrich. Pancreata were digested for 5 min at 37 °C, hand-shaken, and washed three times in cold HBSS solution \[[@pmed-0050206-b041]\]. Islets were isolated by hand under a dissecting microscope and pooled islets were maintained in CMRL-1066 culture medium (GIBCO) supplemented with fetal calf serum (FCS, 10%), penicillin (100 units/ml), and streptomycin (100 μg/ml).

^86^Rb^+^ Efflux Experiments {#s2e}
----------------------------

Isolated islets were pre-incubated with ^86^Rb^+^ (rubidium chloride 1.5 mCi/ml, Amersham Biosciences) for 1 h. Loaded islets were placed in microcentrifuge tubes (30 per group) and washed twice with RPMI-1640 media (Sigma-Aldrich). ^86^Rb^+^ efflux was assayed by replacing the bathing solution with Ringer\'s solution with metabolic inhibitor (MI), with or without 1 μmol/l glibenclamide. MI solution contained 2.5 mg/ml oligomycin, 1 mM 2-deoxyglucose, together with 10 mM tetraethylammonium to block voltage-gated K^+^ channels, 10 μM nifedipine to block Ca^2+^ entry, and 30 mM KCl to maintain Em ∼ 0. The bathing solution was replaced with fresh solution every 5 min over a 40 min period, and counted in a scintillation counter. ^86^Rb efflux was fitted by a single exponential and the reciprocal of the exponential time constant (rate constant) for each efflux experiment is then proportional to the K^+^ (Rb^+^) conductance of the islet membranes.

Insulin Release Experiments {#s2f}
---------------------------

Acutely, following isolation, or after overnight incubation in low-glucose (5.6 mM) CMRL-1066, islets (ten per well in 12-well plates) were preincubated for 30 min in glucose-free CMRL-1066 plus 3 mM D(+)-glucose, then incubated in CMRL-1066 plus different glucose concentration, as indicated. Islets were incubated for 60 min at 37 °C and medium removed and assayed for insulin content. Isolated islets were sonicated on ice prior to estimation of insulin content. Insulin was measured using rat insulin radioimmunoassay according to manufacturer\'s procedure (Linco, <http://www.millipore.com>). Experiments were repeated in triplicate.

Immunohistological Analysis {#s2g}
---------------------------

Pancreata from WT, Kir6.2 KO, and SUR1 KO mice treated for 56 d with placebo or glibenclamide pellets were fixed in 10% formalin and paraffin embedded for serial sectioning (5 μm thick). Hematoxylin-eosin (HE) staining was carried out as described previously \[[@pmed-0050206-b042]\]. For insulin and glucagon immunofluorescence, pancreatic sections were incubated overnight at 37 °C with a guinea pig anti-insulin primary antibody or a guinea pig anti-glucagon primary antibody (1:250 or 1:500, respectively; Linco). Primary antibodies were detected by incubating for 1.5 h at 25 °C with an anti-guinea pig secondary antibody conjugated with the Alexa 488 fluorescent dye (Molecular Probes, <http://www.invitrogen.com>) \[[@pmed-0050206-b042]\]. Apoptosis was assessed on paraffin sections using the TUNEL staining technique (ApopTag Plus Fluorescein In Situ Apoptosis Detection Kit, Chemicon International, httpp://www.millipore.com). DNAase I recombinant (Roche) was used to damage DNA as a positive control for the experiment.

Statistics {#s2h}
----------

Data are presented as mean ± standard error of the mean (SEM). Differences between the non-implanted control group and the pellet-implanted groups were assessed using analysis of variance (ANOVA) within each time point. When significant and within the framework of the ANOVA, the Duncan post hoc test was used to test specific hypotheses about the equivalence of the control group with each test group. When only two groups were compared, unpaired *t*-tests were used to assess significance. Differences were assumed to be significant in each case if *p* \< 0.05. When the sample size was three or less, statistics were not performed and significance is not assigned. Given sample size limitations, we did not use a multilevel model to compare change over time between groups. Unless stated otherwise, asterisks in figures indicate significant difference between the test group and the control group within time point or condition, non-significant differences are not indicated.

Results {#s3}
=======

Glucose Tolerance Is Enhanced and Fed Glucose Is Reduced in WT Mice Acutely Injected with Glibenclamide {#s3a}
-------------------------------------------------------------------------------------------------------

Six-week-old C57BL/6 WT mice simultaneously injected with 1.5 g/kg glucose and glibenclamide (0, 1, 3, 10, and 30 μg) showed a dose-dependent enhancement of glucose tolerance, with a more rapid glucose decline compared with control mice injected with only glucose ([Figure 1](#pmed-0050206-g001){ref-type="fig"}A). Consistent with the well-known acute effect of SUs on blood sugars, and in correlation with the glibenclamide effect on the GTT, these acute injections caused a rapid, dose-dependent drop in blood glucose levels. Importantly, the two highest concentrations of glibenclamide (10 and 30 μg) caused a similar marked reduction of fed blood glucose after an extended period, consistent with a saturated effect of the drug in vivo ([Figure 1](#pmed-0050206-g001){ref-type="fig"}B).

![Acute and Chronic Effect of Glibenclamide on Glucose Tolerance and Blood Glucose Levels\
In each graph, asterisks indicate control group is significantly different (*p* \< 0.05) from the test group at the specified time point.\
(A) GTTs on 6-wk-old WT mice (*n* = 10) fasted for 12 h and intraperitoneally injected with 1.5 g/kg glucose and glibenclamide simultaneously.\
(B) Blood glucose response of fed 6-wk-old mice (*n* = 10) to acute injection of glibenclamide.\
(C) Fed blood glucose from WT and Kir6.2 knockout (Kir6.2KO) mice implanted with placebo or glibenclamide pellets (0.0001 or 2.5 mg/pellet) over time.\
(D) Individual values of fed glucose (plus mean and SEM) from WT control and glibenclamide-pelleted mice, as well as Kir6.2-KO and SUR1-KO mice implanted with 2.5 mg pellets, at 1 and 42 d after implantation.\
Each group in (C) and (D) contained ten to 15 mice.](pmed.0050206.g001){#pmed-0050206-g001}

Biphasic Blood Glucose Response of WT Mice Chronically Treated with Glibenclamide {#s3b}
---------------------------------------------------------------------------------

As discussed in the Introduction, K~ATP~ KO mice show an unexpected phenotype that contradicts the simple prediction for complete inhibition of K~ATP~ channel activity \[[@pmed-0050206-b010]--[@pmed-0050206-b012]\]. We have previously shown that this phenotype depends on complete, or nearly complete loss of K~ATP~, while intermediate loss induces insulin hypersecretion \[[@pmed-0050206-b014]\]. We suggest that this biphasic response profile is a direct consequence of loss of K~ATP~ and resultant hyperexcitability. In order to pharmacologically test this hypothesis, we took advantage of the availability of slow-release implantable drug pellets. Mice were chronically treated with glibenclamide, a specific K~ATP~ channel blocker, by pellet implantation at 6 wk of age. We could thus examine long-term (90 d) effects of the drug, avoiding the peak and valley effect produced by single injections and the stress of frequent injections.

During the first four days following implantation with high-dose slow-release glibenclamide pellets, fed blood glucose levels in WT mice were significantly lower than in placebo-implanted mice ([Figure 1](#pmed-0050206-g001){ref-type="fig"}C), and the glucose-lowering effect was glibenclamide-dose--dependent. The circulating glibenclamide level is unknown in these experiments. However, therapeutic glibenclamide doses in humans are typically around 0.05 mg/kg/d. Pellets containing 0.1 mg released over 90 d should give a similar net dose in a 25 g mouse; thus, the implanted doses (0.0001--2.5 mg) should span therapeutic ranges. The initial decrease in fed blood sugars was lost within a few days, and fed blood glucose was significantly higher in implanted animals after 4--5 d, for all implanted doses except the very lowest 0.0001 mg dose ([Figure 1](#pmed-0050206-g001){ref-type="fig"}C). Two weeks after pellet implantation, all glibenclamide-treated mice (with the exception of those with the 0.0001 mg pellet) showed similar elevated fed blood glucose, and this elevated level persisted without further impairment until 42 d after implantation ([Figure 1](#pmed-0050206-g001){ref-type="fig"}C). The elevation was essentially the same as that seen in placebo-treated K~ATP~ KO mice, with no significant differences between glibenclamide- and placebo-treated KO mice ([Figure 1](#pmed-0050206-g001){ref-type="fig"}C and [1](#pmed-0050206-g001){ref-type="fig"}D).

Impaired Glucose Tolerance in WT Mice Chronically Treated with High Doses of Glibenclamide {#s3c}
------------------------------------------------------------------------------------------

As previously reported, Kir6.2 KO and SUR1 KO mice are less glucose tolerant than WT mice \[[@pmed-0050206-b010]--[@pmed-0050206-b012]\], as illustrated by intraperitoneal GTT ([Figure 2](#pmed-0050206-g002){ref-type="fig"}A). WT mice implanted with high-dose glibenclamide pellets (0.25 and 2.5 mg/pellet, equivalent to a release of 3 and 30 μg/d) showed very rapid progression to impaired glucose tolerance compared to WT placebo-treated mice ([Figure 2](#pmed-0050206-g002){ref-type="fig"}B--[2](#pmed-0050206-g002){ref-type="fig"}D). After only 7 d ([Figure 2](#pmed-0050206-g002){ref-type="fig"}C), and sustained thereafter to at least 42 d postimplantation ([Figure 2](#pmed-0050206-g002){ref-type="fig"}D), glibenclamide-treated mice were as glucose intolerant as KO mice. Moreover, K~ATP~ KO mice chronically treated with glibenclamide show no change in the preexisting glucose-intolerant response. Thus, pharmacological block of the K~ATP~ channel in WT mice essentially reiterates the loss of glucose tolerance seen in K~ATP~ channel KO mice.

![Impaired Glucose Tolerance in Mice Implanted with High Dose Slow-Release Glibenclamide Pellets\
GTTs on WT mice before (A), 2 d (B), 7 d (C), 42 d (D), 95 d (E), and 118 d (F) after implantation of pellets containing high doses of glibenclamide. Each group contained ten mice, except five in (E) and (F). Mice were injected intraperitoneally with glucose (1.5 g/kg). Blood was taken at times indicated and assayed for glucose concentration. In each graph, asterisks indicate control group is significantly different (*p* \< 0.05) from the test group at the specified time point.](pmed.0050206.g002){#pmed-0050206-g002}

Enhanced Glucose Tolerance, but Crossover to a Progressive Impairment of Glucose Tolerance, in Mice Implanted with Low-Dose Glibenclamide Pellets {#s3d}
-------------------------------------------------------------------------------------------------------------------------------------------------

GTTs were also performed in mice implanted with pellets containing much lower doses of glibenclamide ([Figure 3](#pmed-0050206-g003){ref-type="fig"}). An early (2 or 7 d after implantation) mild enhancement of glucose tolerance was detectable in mice implanted with a very low dose of glibenclamide (0.001 or 0.0001 mg/pellet, [Figure 3](#pmed-0050206-g003){ref-type="fig"}B and [3](#pmed-0050206-g003){ref-type="fig"}C, respectively), but this was again followed by a progressive impairment in glucose tolerance over time ([Figures 3](#pmed-0050206-g003){ref-type="fig"}C and [3](#pmed-0050206-g003){ref-type="fig"}D). Again, 42 d postimplantation, 0.001 mg/pellet--treated mice showed similar impairment in glucose tolerance to mice treated with high doses of glibenclamide for the same period of time ([Figures 2](#pmed-0050206-g002){ref-type="fig"}D and [3](#pmed-0050206-g003){ref-type="fig"}D). However, this crossover was markedly delayed with the very lowest dose (0.0001 mg/pellet); at 7 d glucose tolerance was significantly enhanced, although at 42 d, blood glucose and glucose tolerance were similar to control. Thus, at very low doses, the "pelleted" mice resemble heterozygous K~ATP~ knockout mice \[[@pmed-0050206-b013],[@pmed-0050206-b014],[@pmed-0050206-b043]\], at least for a period of 2--7 d.

![Enhancement and Crossover of Glucose Tolerance in Mice Implanted with Low Dose Slow-Release Glibenclamide Pellets\
In each panel, asterisks indicate control group is significantly different (*p* \< 0.05) from the test group at the specified time point.\
GTTs performed on WT mice before (A), 2 d (B), 7 d (C), 42 d (D), 95 d (E), and 118 d (F) after implantation of pellets containing high doses of glibenclamide. Groups contained ten mice each, except five in (E) and (F). Note: The lowest-dose pellets (0.0001 mg) were examined only at 14 and 42 d postimplant.](pmed.0050206.g003){#pmed-0050206-g003}

In Vivo Dose- and Time-Dependent Changes in Insulin Secretion in Response to Glucose Injection in Mice Chronically Treated with Glibenclamide Pellets {#s3e}
-----------------------------------------------------------------------------------------------------------------------------------------------------

Two days after implantation, plasma insulin was very slightly elevated in mice treated with 0.001 mg pellets, but was dose-dependently reduced in all mice treated with higher doses for the same period. At 42 d after glibenclamide treatment, fed plasma insulin was significantly reduced in all implanted mice ([Figure 4](#pmed-0050206-g004){ref-type="fig"}A), paralleling the marked increase in blood sugar ([Figure 1](#pmed-0050206-g001){ref-type="fig"}D), independent of the glibenclamide dose. Glucose-stimulated insulin secretion (GSIS) in vivo was assessed from plasma insulin values 30 min after glucose challenge. Insulin secretion in response to glucose was increased in mice treated with the lowest dose of glibenclamide, consistent with the enhanced glucose tolerance observed in these mice 2 d after drug implantation. Also consistent with changes in glucose tolerance, all other glibenclamide-implanted mice showed a dose-dependent reduction in insulin secretion that worsened over time ([Figure 4](#pmed-0050206-g004){ref-type="fig"}B).

![Drug and Insulin Responsivity In Vivo\
In each graph, asterisks indicate control group is significantly different (*p* \< 0.05) from the test group at the specified time point.\
(A) Individual fed plasma insulin (plus mean and SEM) in glibenclamide-treated mice, 2 d and 42 d after glibenclamide implantation.\
(B) Individual values (plus mean and SEM) of plasma insulin 30 min after glucose injection (normalized to control unpelleted) at either 2 d or 42 d.\
(C and D) WT mice 5 wk implanted with different doses of glibenclamide were intraperitoneally injected with glibenclamide (C) or with insulin (D) and blood glucose was assessed over time.\
(E and F) Control and high-dose glibenclamide-pelleted mice were intraperitoneally injected with 20 mg/kg diazoxide, and blood glucose was assessed over time. In (F), glucose is normalized to the precontrol value (indicated by broken line).](pmed.0050206.g004){#pmed-0050206-g004}

No Effect of Acute Glibenclamide Injection, and Normal Insulin Sensitivity in Mice Chronically Treated with Glibenclamide {#s3f}
-------------------------------------------------------------------------------------------------------------------------

To test whether the glucose-intolerant phenotype of chronically glibenclamide-treated mice is still correlated with loss of function of K~ATP~ channel activity, the response to acute injection of glibenclamide was measured at the times indicated. As expected for complete or near complete inhibition of the channel by the circulating drug levels, injection of glibenclamide produced no significant effect in mice chronically treated with high-dose pellets, and only a modest lowering of blood sugars in mice implanted with low-dose pellets ([Figure 4](#pmed-0050206-g004){ref-type="fig"}C).

To assess insulin sensitivity in peripheral tissues, WT placebo- and glibenclamide-implanted mice were subjected to an ITT. Mice implanted with both low and high doses of glibenclamide showed similar insulin sensitivity to WT-placebo-implanted mice ([Figure 4](#pmed-0050206-g004){ref-type="fig"}D).

Glibenclamide-Treated Islets Exhibit a Marked Reduction of K~ATP~ Conductance {#s3g}
-----------------------------------------------------------------------------

Macroscopic K~ATP~ channel density in freshly isolated (within 2 h) intact islets was assessed by ^86^Rb^+^ efflux under metabolic inhibition to lower cellular \[ATP\]:\[ADP\] and maximally activate available K~ATP~ channels ([Figure 5](#pmed-0050206-g005){ref-type="fig"}). The efflux rate constant (proportional to available K~ATP~ conductance) was significantly reduced in glibenclamide-implanted mice compared with placebo-treated mice, indicating reduced K^+^ conductance. In WT placebo-treated islets, over 70% of the flux was glibenclamide-sensitive; however, WT glibenclamide-treated islets showed less than 40% glibenclamide-sensitive effluxes ([Figure 5](#pmed-0050206-g005){ref-type="fig"}), indicating that K~ATP~ conductance was substantially reduced. Consistent with a reversible effect of the drug to inhibit the channel directly, maintenance of isolated islets from glibenclamide-implanted mice in the absence of the drug for 24 h (in vitro drug washout) show a dramatic recovery of glibenclamide-sensitive K^+^ conductance, without changes in glibenclamide-insensitive ^86^Rb^+^ effluxes ([Figure 5](#pmed-0050206-g005){ref-type="fig"}).

![Glibenclamide-Treated Islets Exhibit a Reduction of Total K~ATP~ Channel Density Macroscopic K~ATP~ channel density in intact islets from WT placebo- and glibenclamide-treated mice was assessed by ^86^Rb^+^ effluxes under metabolic inhibition (MI) in the presence and absence of glibenclamide (glib.). Fluxes were fitted by single exponentials and reciprocal rate constant plotted in the figure (each case contained three animals; no significance assessed). Broken line indicates K~ATP~-independent rate constant, determined by glibenclamide in control islets.](pmed.0050206.g005){#pmed-0050206-g005}

The assay of freshly isolated islets was made within 2 h of isolation, at which point there is clearly significant inhibition of K~ATP~ conductance in islets from implanted mice. However, realizing that full recovery occurs within 24 h, it seems likely that some recovery occurs even within this 2 h, so the measured K~ATP~ activity at that time is at best an upper limit estimate, and channel activity in vivo may have been completely suppressed by the circulating glibenclamide levels.

Chronically Glibenclamide-Treated Mice Show Reduced GSIS from Fresh Isolated Islets, but Restored Normal Insulin Secretion in Drug-Washout Islets {#s3h}
-------------------------------------------------------------------------------------------------------------------------------------------------

In order to assess the effect of long-term glibenclamide treatment on β-cell function directly, pancreatic islets were isolated from either WT or K~ATP~ KO mice after treatment with glibenclamide for 42 d. Insulin content of KO islets was slightly lower than WT islets, but insulin content was not significantly different between placebo- and pellet-implanted animals ([Figure 6](#pmed-0050206-g006){ref-type="fig"}A). However, while freshly isolated islets from WT placebo-treated mice showed robust glucose- and glibenclamide-dependent insulin secretion, glibenclamide-treated WT and K~ATP~ KO islets both showed a similar, severely blunted response to both glucose and glibenclamide ([Figure 6](#pmed-0050206-g006){ref-type="fig"}B). A 24 h incubation in CMRL medium (5.6 mM glucose, glibenclamide washout) restored normal glucose and glibenclamide responses in islets obtained from WT glibenclamide-treated mice ([Figure 6](#pmed-0050206-g006){ref-type="fig"}C), paralleling the recovery of K~ATP~ conductance. However, as expected, insulin secretion was not improved in islets from glibenclamide-treated K~ATP~ KO mice.

![Impaired Glucose-Dependence of Insulin Secretion in Fresh Isolated, but Not in 24-h Incubated Islets from Mice Chronically Treated with Glibenclamide\
(A) Insulin content from glibenclamide-pelleted mice.\
(B and C) Glucose-sensitive insulin secretion from freshly isolated islets (B) and from islets incubated in 5.6 mM glucose for 24 h (C). Insulin release and content was measured by radioimmunoassay. Each group contained ten mice, and samples were assayed in triplicate. Significant differences between glibenclamide-implanted and control are indicated for each assay condition by asterisk.\
There were no significant differences in (A).](pmed.0050206.g006){#pmed-0050206-g006}

Reversal of Phenotype Is also Observed In Vivo {#s3i}
----------------------------------------------

The above results dramatically demonstrate rapid reversibility in vitro of the chronic glucose-desensitizing effects of glibenclamide. Removal of pellets to assess reversibility in vivo is impractical, so instead we examined glucose control in implanted mice, beyond the time at which release should cease (95 or 118 d). In this case, the animals should have been exposed to glibenclamide for the full 90-d release period, but then should have had either 5 d or 28 d without drug exposure. Partial restoration was detectable at 5 d after drug release ([Figures 2](#pmed-0050206-g002){ref-type="fig"}E and [3](#pmed-0050206-g003){ref-type="fig"}E) was terminated, and even mice that had been implanted with 2.5 mg glibenclamide/pellet showed dramatic restoration of both insulin secretion and glucose tolerance 118 d after pellet implantation (i.e., 28 d after the drug release was terminated) ([Figures 2](#pmed-0050206-g002){ref-type="fig"}F and [3](#pmed-0050206-g003){ref-type="fig"}F).

The restoration of secretion following the cessation of glibenclamide release raises the question of whether secretion might also be acutely restored by diazoxide treatment (to activate K~ATP~ and block the hyperexcitability) during the period of glibenclamide release. Acutely, diazoxide may cause glucose to rise, but in "resting" the β-cells may also transiently allow recovery of insulin "releasability," leading to a transient restoration of normal glucose. We performed the experiment on control and high-dose (2.5 mg) pelleted animals. As predicted, there was a rise in glucose in both cases, but a marked subsequent prolonged undershoot only in the pelleted animals ([Figure 4](#pmed-0050206-g004){ref-type="fig"}E and [4](#pmed-0050206-g004){ref-type="fig"}F).

Morphology of Pancreas and α-/β-Cell Distribution within Islets from Glibenclamide-Implanted Mice Is Not Altered {#s3j}
----------------------------------------------------------------------------------------------------------------

The normal content of insulin and rapid recovery of secretion in isolated islets from glibenclamide-treated animals would seem to rule out apoptotic or necrotic effects of the drug on β-cells. However, to confirm this, immunohistochemical analyses were performed on sectioned pancreata from 9-wk glibenclamide-implanted mice. Hematoxylin-eosin staining showed similar pancreatic architecture in glibenclamide-implanted vs. placebo-treated mice ([Figure 7](#pmed-0050206-g007){ref-type="fig"}A, left photomicrographs). Immunostaining for insulin and glucagon confirmed normal distribution of both insulin-containing β-cells and glucagon-containing α-cells, with no obvious changes in islet size ([Figure 7](#pmed-0050206-g007){ref-type="fig"}A, middle and right photomicrographs). No marked redistribution of α-/β-cells or loss of β-cell mass (i.e., reduced insulin immunofluorescence) was observed in glibenclamide-treated mice, although there was a very slight tendency for α-cell infiltration in the core of glibenclamide-treated pancreatic islets. In order to specifically test for the possibility of enhanced β-cell death, in situ immunostaining for apoptosis was performed in paraffin-fixed sections using the TUNEL technique ([Figure 7](#pmed-0050206-g007){ref-type="fig"}B). Pancreatic sections were costained with insulin (green) and TUNEL (red). The absence of red staining in the left images of [Figure 7](#pmed-0050206-g007){ref-type="fig"}B indicates no obvious β-cell apoptosis was present in islets from control or high dose (0.25 and 2.5 mg/pellet) glibenclamide-pelleted mice. As positive control, consecutive pancreatic sections from each sample were treated with recombinant DNAase I, resulting in extensive TUNEL positivity in endocrine as well as exocrine cells ([Figure 7](#pmed-0050206-g007){ref-type="fig"}B, right photomicrographs).

![Morphological and Physiological Response to Chronic Hyperexcitability, and Proposed "Inverse U" Model Response for Enhanced β-Cell Excitability\
(A) Hematoxylin-eosin staining (left), glucagon (middle), and insulin (right) immunostaining of pancreatic paraffin sections from WT control and glibenclamide-implanted mice.\
(B) Insulin (green) and TUNEL (red) staining of pancreatic sections from control and glibenclamide-pelleted mice. Left images show images from untreated sections; right images show islets from paraffin sections treated with recombinant DNAase I (TUNEL-positive controls).\
(C) Proposed "Inverse U" model response for enhanced β-cell excitability: normal islets (white circle) secrete normally, but following a high-fat diet (HFD; grey dashed arrow) progress to insulin hypersecretion. Both Kir6.2\[AAA\] and heterozygous Kir6.2- and SUR1-KO mice (50%--70% decreased K~ATP~ activity with increased excitability) hypersecrete (grey circles, solid line) and are positioned on the "ascending limb" of the curve \[[@pmed-0050206-b013],[@pmed-0050206-b014],[@pmed-0050206-b043]\]. HFD causes further enhancement of excitability, beyond the threshold driving those islets "over the top" (dashed) to an undersecretory phenotype. Conversely, Kir6.2- and SUR1-KO islets (zero K~ATP~ channel activity), which have maximally enhanced excitability, hypersecrete as neonates (grey circle on solid line), but rapidly progress to an undersecretory phenotype (black circle on solid line), and are positioned on the "descending limb" \[[@pmed-0050206-b010]--[@pmed-0050206-b012]\]. Glibenclamide-treated WT mice rapidly progress from normal insulin secretion to undersecretion (white circle on "ascending limb" is converted to black circle on "descending limb"). This phenotype can be completely reversed when hyperexcitability is removed (small black dashed line). Finally, mice expressing mutant β-cell K~ATP~ channels with enhanced activity (Kir6.2\[ΔN30\]) \[[@pmed-0050206-b041]\] have a severely undersecreting phenotype, extending the ascending limb beyond the position of normal animals.](pmed.0050206.g007){#pmed-0050206-g007}

Discussion {#s4}
==========

In the present study, we examined the "inverse U" hypothesis to explain the response to enhanced excitability, in which excessive hyperexcitability drives β-cells to insulin secretory failure \[[@pmed-0050206-b014],[@pmed-0050206-b042]\], using a novel approach of implanting mice with slow-release sulfonylurea (glibenclamide) pellets, to chronically inhibit β-cell K~ATP~ channels. Glibenclamide-implanted wild-type mice became progressively and consistently diabetic, with significantly reduced insulin secretion in response to glucose. After 1 wk of treatment, these mice were as glucose intolerant as adult K~ATP~ knockout mice, with similar loss of secretory capacity. However, secretory capacity was fully restored in these islets within hours of drug washout in vitro, or within 1 mo after glibenclamide treatment was terminated in vivo. Pancreatic immunostaining showed normal islet size and α-/β-cell distribution within the islet, and TUNEL staining showed no evidence of apoptosis.

Hyperexcitability and Hyperinsulinism in Animal Models and Humans: Key Features and Discrepancies {#s4a}
-------------------------------------------------------------------------------------------------

Glucose metabolism increases the β-cell \[ATP\]:\[ADP\] ratio, leading to closure of K~ATP~ channels, membrane depolarization and Ca^2+^ influx. The resultant rise in intracellular Ca^2+^ (\[Ca^2+^\]~i~) triggers insulin secretion. Reduced or absent K~ATP~ channel activity is expected to result in constitutive membrane depolarization, elevated \[Ca^2+^\]~i~, and hypersecretion of insulin. Consistent with this prediction, loss-of-function mutations of K~ATP~ channel subunits (SUR1, *ABCC8* or Kir6.2, *KCNJ11*) underlie congenital HI in humans \[[@pmed-0050206-b009]\]. Conversely, gain-of-function mutations of Kir6.2 or SUR1 are expected to cause an undersecreting phenotype and hypoinsulinemia---and consistent with this prediction, activating mutations in K~ATP~ cause both permanent and transient neonatal diabetes \[[@pmed-0050206-b044],[@pmed-0050206-b045]\].

Genetic manipulation of K~ATP~ channel subunits in mice has confirmed some of the basic expectations of the above paradigm and reiterated some features of human disease, although conflicting and contradictory findings illustrate additional complexities, particularly for models of reduced K~ATP~ channel activity. Mice that completely lack K~ATP~ channels do not reiterate the HI phenotype in any simple way. In these mice, hypersecretion reportedly occurs immediately after birth, but there is rapid progression to a relative undersecretion and glucose intolerance \[[@pmed-0050206-b010]--[@pmed-0050206-b012]\]. There is thus an apparent discrepancy between the outcome of genetic loss of K~ATP~ channels in mice and humans. One important potential caveat to consider is whether patients typically have a complete loss of K~ATP~ channels, and therefore whether complete KO mice are appropriate models for the disease. Both trafficking and functional mutations will probably tend to cause only a relative loss of K~ATP~ conductance. Mice expressing a dominant-negative Kir6.2\[AAA\] transgene in β-cells, as well as mice heterozygous for Kir6.2 or SUR1, may model such a condition, since they show substantial, but incomplete, reduction of K~ATP~ channel activity (∼60%--70%). All of these models demonstrate both an enhanced glucose stimulation of insulin secretion and hyperinsulinism that persists through adulthood \[[@pmed-0050206-b013],[@pmed-0050206-b014],[@pmed-0050206-b043]\].

Biphasic Response to K~ATP~ Inhibition: Pharmacological Verification of the "Inverse-U" Model for β-Cell Response to Hyperexcitability {#s4b}
--------------------------------------------------------------------------------------------------------------------------------------

We therefore propose that varying degrees of genetic suppression of K~ATP~ channels will all lead to enhanced excitability and insulin secretion, but with potentially very different long-term consequences depending on the severity of suppression: incomplete loss of K~ATP~ channels (e.g., in Kir6.2\[AAA\] or in heterozygous Kir6.2^+/−^ or SUR1^+/−^ mice) causes a persistent hyperinsulinism, whereas complete loss (e.g., in K~ATP~ KO mice) may transiently cause hypersecretion, but this is followed by a secretory deficit and reduced glucose tolerance ([Figure 7](#pmed-0050206-g007){ref-type="fig"}C) \[[@pmed-0050206-b014],[@pmed-0050206-b042]\].

We suggest that this model may be generalizable to hyperexcitability resulting from any other mechanism, such as loss of other K^+^ conductances, or gain of excitatory current. However, it is important to note that the model is developed solely from experiments with genetic manipulation of K~ATP~ channel subunits, and requires verification by direct manipulation of excitability in genetically normal animals. In the present study we have successfully performed just such an experiment by utilizing slow-release implanted drug pellets. This approach allowed us to pharmacologically block K~ATP~ channels over a prolonged period in a tractable in vivo model. The dramatic consequence is that although blood glucose levels are initially lowered and glucose tolerance is enhanced ([Figures 1](#pmed-0050206-g001){ref-type="fig"} and [3](#pmed-0050206-g003){ref-type="fig"}), within a few days the phenotype crosses over to hyperglycemia and glucose intolerance that is strikingly similar to the adult phenotype of K~ATP~ KO mice for all except the very lowest-dose pellets. Earlier studies of "long-term" treatment of animals with sulfonylureas have generally not gone beyond a few days \[[@pmed-0050206-b046]\], presumably due to the practical difficulties of injection regimens. Importantly, young mice injected daily with glibenclamide showed a degranulation effect in their β-cells, which might explain the reduced secretory capacity, although this effect was apparently not present in older mice \[[@pmed-0050206-b047]\]. Increased basal insulin secretion but reduced glucose- and glibenclamide-stimulated insulin secretion have been seen from isolated islets exposed in vitro to glibenclamide for 24 h \[[@pmed-0050206-b048],[@pmed-0050206-b049]\], due to prolonged glibenclamide action and reduced insulin content \[[@pmed-0050206-b049]\]. Similarly, chronic exposure of rat pancreatic islets to sulfonylureas caused reversible impairment of glucose- and sulfonylurea-induced insulin release \[[@pmed-0050206-b050]--[@pmed-0050206-b052]\]. While short-term (24 h) exposure of insulinoma cell lines to SUs induced an increase in GLUT2 and GK mRNA, long-term (48--72 h) exposure induced a marked reduction of these glucose mobilizers \[[@pmed-0050206-b053]\], coupled with a reversible reduction in insulin content with no changes in Kir6.2 or SUR1 transcripts (72--144 h) \[[@pmed-0050206-b039]\]. Here we demonstrate that intact mice treated with chronic glibenclamide show no significant changes in islet insulin content, although a very mild reduction in insulin content was found in islets from mice implanted with the highest dose ([Figure 6](#pmed-0050206-g006){ref-type="fig"}). Instead, our results indicate very specifically that chronic glibenclamide treatmen*t* in vivo induces β-cell desensitization (impairment of insulin secretion) rather than inhibition of insulin production \[[@pmed-0050206-b054]\]. ^86^Rb^+^-efflux experiments on fresh isolated islets from glibenclamide-implanted mice demonstrate that substantial inhibition of K~ATP~ activity is present ([Figure 5](#pmed-0050206-g005){ref-type="fig"}), which predicts hyperexcitability and elevated \[Ca^2+^\], as has been seen in K~ATP~ KO animals. This would in turn stimulate insulin secretion, which suggests that the impairment of secretion is at a stage downstream of Ca^2+^, presumably at the level of insulin production or mobilization, or at the level of β-cell mass. There is a remarkable and rapid recovery of both K~ATP~ activity and normal insulin secretion within 24 h of islet isolation from these mice, arguing against β-cell apoptosis or other types of cell death induced by chronic glibenclamide treatment in vivo, and supported by the immunhistological analyses in [Figure 7](#pmed-0050206-g007){ref-type="fig"}A and [7](#pmed-0050206-g007){ref-type="fig"}B.

Clearly, recovery of both K~ATP~ conductance and secretion is rapid (within hours of removal of islets from the animal), and although unassessable, the most reasonable explanation is that the recovery results simply from the washout of the drug and reversal of the resultant chronic depolarization. However, the formal possibility remains that the recovery is due to loss of other neuronal or hormonal inputs present in the intact animal. The level of K~ATP~ activity in [Figure 5](#pmed-0050206-g005){ref-type="fig"}, assessed about 2 h after isolation, is an upper limit estimate, since some recovery may already have occurred and, in vivo, the degree of inhibition may be considerably greater. That this is likely is illustrated in [Figure 5](#pmed-0050206-g005){ref-type="fig"}: except for the very lowest dose of implanted glibenclamide pellets, the glucose-lowering effect of injected glibenclamide, which reflects the degree of K~ATP~ inhibition possible, was negligible.

The "Inverse U" Model Is Reversible: Removal of the Hyperexcitable Stimulus Restores Normal Responsivity {#s4c}
--------------------------------------------------------------------------------------------------------

In the genetic models of hyperexcitability, progression onto the "descending limb" of the "inverse U" response is permanent; glucose intolerance persists throughout the lifetime of K~ATP~ KO animals, and in reduced K~ATP~ animals when under dietary stress. However, it appears that this progression is rapidly reversible if excitability is normalized (as we show here), or if the dietary stress is removed \[[@pmed-0050206-b042]\]. As we discuss further below, various studies have suggested that "resting" pancreatic β-cells, by exogenous suppression of blood glucose, can restore function in diabetic states. This is the case for high-fat diet--induced glucose intolerance in Kir6.2^+/−^\[AAA\] mice \[[@pmed-0050206-b042]\]. Within 2 wk of restoration of normal diet, Kir6.2^+/−^\[AAA\] mice recover secretory capacity and glycemic control to near normal \[[@pmed-0050206-b042]\]. Genetic restoration of excitability has not been attempted in KO mice, but the present study allows us to begin to assess the lability of this effect. First, the pellets are designed to release at the appropriate dose for ∼90 d. The hyperglycemia and hypoinsulinism that develop within a few days of pellet implantation is maintained for at least 6 wk (42 d, [Figures 1](#pmed-0050206-g001){ref-type="fig"} and [4](#pmed-0050206-g004){ref-type="fig"}), and we did not routinely monitor animals after this time. However, we did assess a small number of animals at 95 and 118 d after implantation, i.e., 5 and 28 d after the pellets should have stopped releasing. By 1 mo, glucose tolerance is restored ([Figures 2](#pmed-0050206-g002){ref-type="fig"}F and [3](#pmed-0050206-g003){ref-type="fig"}F) and even at only 5 d there is marked normalization of blood glucose and glucose tolerance ([Figures 2](#pmed-0050206-g002){ref-type="fig"}E and [3](#pmed-0050206-g003){ref-type="fig"}E). These results strongly demonstrate that insulin secretory failure in response to loss-of-K~ATP~ activity is reversible, if hyperexcitability is removed.

More dramatically, isolated islets from implanted mice reveal rapid reversibility at the cellular level. Within a few hours of removal from the circulating glibenclamide, isolated islets regain not only essentially normal K~ATP~ activity but they regain essentially normal GSIS too. This means that whatever underlying mechanism causes the secretory failure, it is fully and rapidly reversible. Although 5.6 mM glucose is not particularly high, the finding that overnight incubation is sufficient to restore the secretory response to glucose in these islets may have parallels with the recent finding that overnight incubation of SUR1 KO islets in elevated (10 mM) glucose also restores insulin secretory capacity \[[@pmed-0050206-b055]\].

Relevance of the Present Findings for Type 2 Diabetes {#s4d}
-----------------------------------------------------

The present findings have implications both for the potential etiology of type 2 diabetes and for pharmacological intervention. People with type 2 diabetes typically experience a gradual loss of secretory function. In many patients, SUs effectively control glycemia for an extended period \[[@pmed-0050206-b033]\], but over the long term (months to years) SU therapies often fail \[[@pmed-0050206-b033],[@pmed-0050206-b056],[@pmed-0050206-b057]\]. Several animal studies \[[@pmed-0050206-b028],[@pmed-0050206-b058],[@pmed-0050206-b059]\] and studies of isolated islets and cells \[[@pmed-0050206-b037],[@pmed-0050206-b052]\] provide evidence that long-term SU treatment leads to impaired glucose tolerance and GSIS. The present study shows a markedly impaired secretory response to chronic glibenclamide that can be rapidly reversed following removal of the drug in vitro. In the implanted animals, glibenclamide release is continuous, and in patients, dosing is pulsatile. Conceivably, pulsatile presentation may provide islets with unstimulated periods that allow restoration of secretory capacity and responsivity. This rationale may suggest that lower-potency, shorter-acting SUs might be more efficacious therapeutically. In nonobese people with type 2 diabetes, including those in whom SUs secondarily fail, there are reports of significant restoration of β-cell secretory activity after a brief period of intensive insulin therapy \[[@pmed-0050206-b060],[@pmed-0050206-b061]\]. This finding may argue for re-evaluation of short-acting analogs and give cause to further consider approaches \[[@pmed-0050206-b062]\] to reverse loss of secretory response in patients with type 2 diabetes following long-term SU treatment, and thereby prolong the use of pharmacotherapies and delay the need to switch to insulin.
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GSIS

:   glucose-stimulated insulin secretion

GTT

:   glucose tolerance test

HI

:   hyperinsulinism

ITT

:   insulin tolerance test

KO

:   knock-out

SEM

:   standard error of the mean

SU

:   sulfonylurea

TUNEL

:   terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling
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